Regenerative biologics
Mesenchymal stem cell therapy (intravenous, allogeneic laromestrocel)
Graded on: 6-minute walk distance and physical function in diagnosed aging frailty.
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
Compare this record with another, side by side →
How this letter has changedLatest: October 2026 · Corrected.
The record's title covered allogeneic intravenous MSCs in general while its grade rests on one developer's bone marrow-derived product, so the title now says so. The grade basis said nothing had replicated The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. Ruiz 2026 (PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 41747733); it now names the open-label Everyone in the trial knows which treatment they are receiving, so expectations can shape the results, especially for symptoms people report themselves. umbilical cord trial (Nguyen et al., EBioMedicine, 2026; PMID 42019090) and the Zhu 2024 secondary outcomes (PMID 38679727) and explains why a different product in an unblinded design does not count, with the systematic review that could not pool the three trials (Poutouri et al., 2026; PMID 42737497). Tompkins 2017 (PMID 28977399) is relabeled: safety primary, walk gain in one dose arm only. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).PMID 28977399 PMID 38679727 PMID 41747733 PMID 42019090 PMID 42737497
Funding stated in the evidence. Ruiz 2026 (PMID 41747733) was NIH-funded and its senior author is chief scientific officer and an equity holder of Longeveron, maker of the cells; Tompkins 2017 (PMID 28977399) was foundation-funded with Longeveron employees among the authors; the Chinese trial Zhu 2024 (PMID 38679727) was government-funded. Letter unchanged.PMID 41747733 PMID 28977399 PMID 38679727
Every change to a letter on this site is dated and published. The full evidence log →
Mesenchymal stem cells are cells taken from a donor and given by IV. In one study of 148 older adults with frailty, one specific stem cell product helped people walk about 63 meters farther in six minutes after nine months. The true effect could be large or small. No one has repeated the study with the same product. This record covers that product only, not stem cell clinics in general.
A letter describes the human evidence, not the product, the manufacturer, or the intervention's worth.
See the full evidence record →Graded on 6-minute walk distance and physical function in diagnosed aging frailty.
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C. The evidence is better than the category's reputation and weaker than its marketing.
WHAT SUPPORTS ITRuiz 2026 (PMID 41747733) is a genuine randomized trial at moderate scale whose primary endpoint The one outcome a trial names in advance as its main test. Results on other outcomes carry less weight. was objectively measured function, not a biomarker A measurable sign in the body, such as a blood test value, used to track a condition or the effect of a treatment.. The 63.4 m point estimate clears every published threshold for a meaningful change in 6-minute walk distance in older adults, including the large-change mark near 50 m. The 95% confidence interval The range the true effect probably falls in. A wide interval means the estimate is uncertain. runs from 17.1 to 109.6 m, and its lower bound sits below the minimal important difference reported for frail older adults, so the trial is consistent with an effect that matters and equally consistent with one that does not. An objectively measured functional outcome does not cap the grade under the EBL rubric, so B was arguable.
WHY IT IS HELD AT Cnothing has replicated it with the same product, and the rubric puts a single positive trial no one has independently repeated at C however well run it is. Two randomized trials of a different product, umbilical cord-derived cells, reported better grip strength and timed up and go as secondary endpoints An outcome a trial also measures but did not choose as its main test. (Zhu 2024, PMID 38679727) and a higher Short Physical Performance Battery score in an open-label design (Nguyen 2026, PMID 42019090); a different cell source in an unblinded trial does not replicate laromestrocel, and a 2026 systematic review found the three trials too heterogeneous to pool (Poutouri 2026, PMID 42737497). The same trial's month 6 result also did not reach significance (p=0.0635), so the primary endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. was met at one timepoint and missed at another inside one dose-finding study. Tompkins 2017 (PMID 28977399) enrolled 30 people with safety as its primary endpoint, and its walk gain appeared in one dose group only; Zhu 2024 (PMID 38679727)'s primary endpoint was self-report. B would assert the effect is established, and it is not.
WHAT THIS DOES NOT COVERevery trial cited here enrolled people with diagnosed aging frailty and measured physical function. None studied healthy adults, none measured lifespan, and none supports the general rejuvenation claim under which this is usually sold.
WHAT THIS RECORD GRADESintravenous allogeneic bone marrow-derived cells of one developer, laromestrocel, in diagnosed aging frailty. Umbilical cord, adipose and other MSC products sold in clinics are different products and are not graded by these trials. Every laromestrocel trial is maker-linked, as the funding line states.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
An intravenous infusion of an allogeneic cell product, given in a research setting. The trial this grade rests on randomized 148 people; a trial that size establishes an effect on walking distance and cannot characterize an uncommon harm. No caution here should be read as a safety record.
The evidence, in fullFive papers, each linked to its PubMed record.
Ruiz et al. (Cell Stem Cell, 2026; PMID 41747733) - randomized dose-finding trial, N=148 ambulatory adults with frailty, allogeneic bone-marrow MSCs (laromestrocel). Primary endpoint was the 6-minute walk test: +63.4 m versus placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received. at month 9 (95% CI 17.1 to 109.6, p=0.0077), but +41.3 m at month 6 did not reach significance (95% CI -2.4 to 84.9, p=0.0635). Tompkins et al. (J Gerontol A Biol Sci Med Sci, 2017; PMID 28977399) - phase II randomized double-blind Neither the participants nor the people assessing them know who received the real treatment until the trial ends. placebo-controlled dose-finding study in 30 patients with aging frailty whose primary endpoint was safety; the 6-minute walk improvement was a secondary finding in the 100 million cell group only, with no gain at 200 million cells. Zhu et al. (Stem Cell Res Ther, 2024; PMID 38679727) - randomized double-blind placebo-controlled trial of umbilical cord-derived MSCs in aging frailty; the primary endpoint was the SF-36 physical component score, which is self-reported; among objective secondary outcomes, timed up and go and grip strength improved while the 4-meter walk did not (p=0.21). Nguyen et al. (EBioMedicine, 2026; PMID 42019090) - open-label randomized phase 2 trial of umbilical cord-derived MSCs in 147 frail adults aged 60 to 85, funded by the hospital's parent company; Short Physical Performance Battery 1.1 points higher at nine months. Poutouri et al. (Int J Mol Sci, 2026; PMID 42737497) - systematic review of the three randomized frailty trials: signals of benefit on mobility, heterogeneity How much the results of the pooled trials differ from each other. High heterogeneity makes a combined estimate less reliable. too great to pool. Grade C. Funding: Ruiz 2026 (PMID 41747733) was supported by NIH grants and its senior author is chief scientific officer, a paid consultant, a board member and an equity holder of Longeveron Inc., which makes the cells tested; Tompkins 2017 (PMID 28977399) was funded by the Soffer Family Foundation and the Starr Foundation, with Longeveron employees and consultants among the authors and the same senior author a Longeveron shareholder; Zhu 2024 (PMID 38679727) was funded by Chinese government programs with no company involvement declared.
6-minute walk distance, gait speed, grip strength. Not a biomarker panel.
Evidence notes: randomized trial, not independently replicated
Endpoint graded: 6-minute walk distance and physical function in diagnosed aging frailty (functional)
Last reviewed: August 2026
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Primary evidenceFive papers, each linked to its PubMed record.
Ruiz et al. (Cell Stem Cell, 2026; PMID 41747733) - randomized dose-finding trial, N=148 ambulatory adults with frailty, allogeneic bone-marrow MSCs (laromestrocel). Primary endpoint was the 6-minute walk test: +63.4 m versus placebo at month 9 (95% CI 17.1 to 109.6, p=0.0077), but +41.3 m at month 6 did not reach significance (95% CI -2.4 to 84.9, p=0.0635). Tompkins et al. (J Gerontol A Biol Sci Med Sci, 2017; PMID 28977399) - phase II randomized double-blind placebo-controlled dose-finding study in 30 patients with aging frailty whose primary endpoint was safety; the 6-minute walk improvement was a secondary finding in the 100 million cell group only, with no gain at 200 million cells. Zhu et al. (Stem Cell Res Ther, 2024; PMID 38679727) - randomized double-blind placebo-controlled trial of umbilical cord-derived MSCs in aging frailty; the primary endpoint was the SF-36 physical component score, which is self-reported; among objective secondary outcomes, timed up and go and grip strength improved while the 4-meter walk did not (p=0.21). Nguyen et al. (EBioMedicine, 2026; PMID 42019090) - open-label randomized phase 2 trial of umbilical cord-derived MSCs in 147 frail adults aged 60 to 85, funded by the hospital's parent company; Short Physical Performance Battery 1.1 points higher at nine months. Poutouri et al. (Int J Mol Sci, 2026; PMID 42737497) - systematic review of the three randomized frailty trials: signals of benefit on mobility, heterogeneity too great to pool. Grade C. Funding: Ruiz 2026 (PMID 41747733) was supported by NIH grants and its senior author is chief scientific officer, a paid consultant, a board member and an equity holder of Longeveron Inc., which makes the cells tested; Tompkins 2017 (PMID 28977399) was funded by the Soffer Family Foundation and the Starr Foundation, with Longeveron employees and consultants among the authors and the same senior author a Longeveron shareholder; Zhu 2024 (PMID 38679727) was funded by Chinese government programs with no company involvement declared.
This page carries a letter. EBL takes no commission, referral fee or payment of any kind on anything it grades. No letter has been bought and none is for sale. Products listed under this modality may be commercial partners, and their purchase links may earn EBL a commission. Those products carry no letter of their own, every relationship is disclosed beside the link, and where a product does not deliver what the trials tested, this page says so regardless of who pays.
How this is enforced
That is not a promise, it is a build condition. Two checks run on every deploy: one refuses to publish if a commission is claimed on anything graded, the other refuses if a page names a commercial relationship that is not declared in the register. If either fails, this page does not go live. You can read how the checks work, and what they do not cover, on the evidence integrity page.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc.. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →